Beswick L - Search Results

1

Management, outcomes and survival of an Australian IgG4-SC cohort: The MOSAIC study.

Kemp W, Majeed A, Mitchell J, Majumdar A, Tse E, Skoien R, Croagh D, Dev A, Gao H, Weltman M, Craig P, Stuart K, Cheng W, Edmunds S, Lee E, Sood S, Metz A, Thompson A, Sinclair M, Beswick L, Nicoll A, Riordan S, Braund A, Muller K, MacQuillan G, Sandanayake N, Shackel N, Roberts SK. Kemp W, et al. Among authors: beswick l. Liver Int. 2021 Dec;41(12):2934-2943. doi: 10.1111/liv.15036. Epub 2021 Sep 3. Liver Int. 2021. PMID: 34392596

2

Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease.

Vasudevan A, Beswick L, Friedman AB, Moltzen A, Haridy J, Raghunath A, Sparrow M, van Langenberg D. Vasudevan A, et al. Among authors: beswick l. Dig Liver Dis. 2018 Jul;50(7):682-688. doi: 10.1016/j.dld.2018.02.001. Epub 2018 Feb 10. Dig Liver Dis. 2018. PMID: 29525182

3

Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients.

Costello SP, Ghaly S, Beswick L, Pudipeddi A, Agarwal A, Sechi A, O'Connor S, Connor SJ, Sparrow MP, Bampton P, Walsh AJ, Andrews JM; Australian Inflammatory Bowel Disease Association (AIBDA). Costello SP, et al. Among authors: beswick l. Intern Med J. 2015 Jun;45(6):659-66. doi: 10.1111/imj.12732. Intern Med J. 2015. PMID: 25732268

4

Never underestimate inflammatory bowel disease: High prevalence rates and confirmation of high incidence rates in Australia.

Studd C, Cameron G, Beswick L, Knight R, Hair C, McNeil J, Desmond P, Wilson J, Connell W, Bell S. Studd C, et al. Among authors: beswick l. J Gastroenterol Hepatol. 2016 Jan;31(1):81-6. doi: 10.1111/jgh.13050. J Gastroenterol Hepatol. 2016. PMID: 26222770

5

Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study.

Motaganahalli S, Beswick L, Con D, van Langenberg DR. Motaganahalli S, et al. Among authors: beswick l. Intern Med J. 2019 Jan;49(1):94-100. doi: 10.1111/imj.14027. Intern Med J. 2019. PMID: 29962008

6

Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis.

Beswick L, Ye B, van Langenberg DR. Beswick L, et al. Inflamm Bowel Dis. 2016 Dec;22(12):2966-2976. doi: 10.1097/MIB.0000000000000958. Inflamm Bowel Dis. 2016. PMID: 27763950 Review.

7

Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response.

Ghaly S, Costello S, Beswick L, Pudipeddi A, Agarwal A, Sechi A, Antoniades S, Headon B, Connor S, Lawrance IC, Sparrow M, Walsh AJ, Andrews JM; AIBDA. Ghaly S, et al. Among authors: beswick l. Intern Med J. 2015 Feb;45(2):170-7. doi: 10.1111/imj.12621. Intern Med J. 2015. PMID: 25370691

8

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study.

Beswick L, Rosella O, Rosella G, Headon B, Sparrow MP, Gibson PR, van Langenberg DR. Beswick L, et al. J Crohns Colitis. 2018 Feb 28;12(3):289-297. doi: 10.1093/ecco-jcc/jjx146. J Crohns Colitis. 2018. PMID: 29121178

9

Author reply.

Chand S, Hair C, Beswick L. Chand S, et al. Among authors: beswick l. Intern Med J. 2021 Jan;51(1):154. doi: 10.1111/imj.15152. Intern Med J. 2021. PMID: 33572009 No abstract available.

10

The role of thiopurine metabolite monitoring in inflammatory bowel disease.

Beswick L, Friedman AB, Sparrow MP. Beswick L, et al. Expert Rev Gastroenterol Hepatol. 2014 May;8(4):383-92. doi: 10.1586/17474124.2014.894878. Epub 2014 Mar 31. Expert Rev Gastroenterol Hepatol. 2014. PMID: 24684593 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

35 results

Search Page